MENU
+Compare
CHEK
Stock ticker: NASDAQ
AS OF
Apr 24, 04:49 PM (EDT)
Price
$0.67
Change
+$0.02 (+3.08%)
Capitalization
18.19M

CHEK Check-Cap Ltd Forecast, Technical & Fundamental Analysis

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC... Show more

CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CHEK with price predictions
Apr 23, 2025

CHEK's Stochastic Oscillator is sitting in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CHEK's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on CHEK as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHEK advanced for three days, in of 215 cases, the price rose further within the following month. The odds of a continued upward trend are .

CHEK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CHEK turned negative on April 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHEK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.593) is normal, around the industry mean (23.728). P/E Ratio (0.000) is within average values for comparable stocks, (81.831). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (41.794).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CHEK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHEK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
CHEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CHEK is expected to report earnings to fall 20.37% to -86 cents per share on April 04

Check-Cap Ltd CHEK Stock Earnings Reports
Q4'23
Est.
$-0.86
Q4'24
Missed
by $0.91
Q3'23
Beat
by $0.39
Q2'23
Missed
by $0.73
Q1'23
Missed
by $0.21
The last earnings report on February 26 showed earnings per share of -108 cents, missing the estimate of -17 cents. With 13.24K shares outstanding, the current market capitalization sits at 18.19M.
A.I. Advisor
published General Information

General Information

a developer of gastrointestinal imaging devices

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
29 Abba Hushi Avenue
Phone
+972 48303400
Employees
85
Web
https://www.check-cap.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HHH66.870.81
+1.23%
Howard Hughes Holdings
CANF1.180.01
+0.85%
Can-Fite BioPharma Ltd
EQR69.380.45
+0.65%
Equity Residential
MNRO14.35-0.05
-0.31%
Monro
BTMD3.43-0.05
-1.44%
Biote Corp

CHEK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CHEK has been loosely correlated with IINN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CHEK jumps, then IINN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
-0.46%
IINN - CHEK
36%
Loosely correlated
+4.52%
NVNO - CHEK
27%
Poorly correlated
+3.45%
TWST - CHEK
26%
Poorly correlated
+1.84%
RSLS - CHEK
26%
Poorly correlated
-2.00%
ICAD - CHEK
26%
Poorly correlated
+1.92%
More